Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.

Biomarkers, Tumor / blood Case-Control Studies Cell Count Disease-Free Survival Flow Cytometry Head and Neck Neoplasms / blood Humans Neoplasm Recurrence, Local / pathology Neoplastic Cells, Circulating / pathology Prognosis Prospective Studies Squamous Cell Carcinoma of Head and Neck / blood

Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
10 2019
Historique:
received: 10 04 2019
accepted: 01 07 2019
pubmed: 8 8 2019
medline: 6 6 2020
entrez: 8 8 2019
Statut: ppublish

Résumé

This prospective multicenter study evaluated the prognostic value of circulating tumor cells (CTCs) in relapsing nonoperable or metastatic head and neck squamous cell carcinoma (rHNSCC) treated by chemotherapy and cetuximab. In 65 patients suitable for analyses, peripheral blood was taken at day 0 (D At D CTCs can be detected before and during chemotherapy in patients with rHNSCC. D NCT02119559.

Sections du résumé

BACKGROUND
This prospective multicenter study evaluated the prognostic value of circulating tumor cells (CTCs) in relapsing nonoperable or metastatic head and neck squamous cell carcinoma (rHNSCC) treated by chemotherapy and cetuximab.
METHODS
In 65 patients suitable for analyses, peripheral blood was taken at day 0 (D
RESULTS
At D
CONCLUSIONS
CTCs can be detected before and during chemotherapy in patients with rHNSCC. D
CLINICALTRIALSGOV IDENTIFIER
NCT02119559.

Identifiants

DOI: 10.1373/clinchem.2019.305904 PMID: 31387885
pubmed: 31387885
pii: clinchem.2019.305904
doi: 10.1373/clinchem.2019.305904
doi:

Substances chimiques

Biomarkers, Tumor 0

Banques de données

ClinicalTrials.gov
['NCT02119559']

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1267-1275

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2019 American Association for Clinical Chemistry.

Auteurs

Renaud Garrel (R)

Department of Head Neck Cancer and Laryngology, University Medical Center of Montpellier, Montpellier, France.

Martine Mazel (M)

Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France.

Françoise Perriard (F)

Department of Biostatistics, UPRES EA2415, Clinical Research University Institute, Montpellier, France.

Marie Vinches (M)

Medical Oncology Department, Institute of Cancer of Montpellier, Montpellier, France.

Laure Cayrefourcq (L)

Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France.

Joël Guigay (J)

Medical Oncology Department, Antoine Lacassagne Cancer Research Center, Nice, France.

Laurence Digue (L)

Department of Medical Oncology, University Medical Center of Bordeaux University Hospital-CHU Bordeaux, Bordeaux, France.

Karine Aubry (K)

Department of Head and Neck Surgery, University Hospital Center of Limoges, Limoges, France.

Marc Alfonsi (M)

Department of Radiation Oncology, Clinique Sainte Catherine, Avignon, France.

Jean-Pierre Delord (JP)

Medical Oncology Department, Claudius Regaud Institute Oncopole, Toulouse, France.

Benjamin Lallemant (B)

Department of Head and Neck Surgery, University Hospital Center of Nîmes, Nîmes, France.

Caroline Even (C)

Department of Head and Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Jean-Pierre Daurès (JP)

Department of Biostatistics, UPRES EA2415, Clinical Research University Institute, Montpellier, France.

Paul Landais (P)

Department of Biostatistics, UPRES EA2415, Clinical Research University Institute, Montpellier, France.

Didier Cupissol (D)

Medical Oncology Department, Institute of Cancer of Montpellier, Montpellier, France.

Catherine Alix-Panabières (C)

Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France; c-panabieres@chu-montpellier.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études cas-témoins › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Numération cellulaire › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Techniques d'investigation › Techniques cytologiques › Cytophotométrie › Cytométrie en flux › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › Cellules tumorales circulantes › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Diagnostic › Pronostic › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Circulating Tumor Cells as a Prognostic Factor...
questionsmedicales.fr › Tumeurs › Tumeurs par siège › Tumeurs de la tête et du cou › Carcinome épidermoïde de la tête et du cou › Circulating Tumor Cells as a Prognostic Factor...